Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
J Natl Cancer Inst
    April 2026
  1. O'CONNELL CP, Burns KF, Hong HG, Kahle L, et al
    Title: Ultra-processed food intake and postmenopausal breast cancer risk in the NIH-AARP diet and health study.
    J Natl Cancer Inst. 2026 Apr 21:djag124. doi: 10.1093.
    >> Share

  2. SPOOR J, Mureau MAM, de Jong D, Tissier RLM, et al
    Risk of autoimmune and rheumatic diseases in breast cancer patients with silicone breast implants.
    J Natl Cancer Inst. 2026 Apr 19:djag115. doi: 10.1093.
    >> Share

  3. JAYASEKERA J, Hooshmand S, Strassle PD, Schneider J, et al
    Breast cancer mortality by age and race and/or ethnicity across counties in the United States, 2000-2019.
    J Natl Cancer Inst. 2026 Apr 3:djag103. doi: 10.1093.
    >> Share

  4. NG DQ, Heshmatipour M, Trudeau J, Sridhar A, et al
    Electroacupuncture improves cognitive function and neuropsychiatric symptoms in breast cancer survivors: a pilot randomized controlled trial.
    J Natl Cancer Inst. 2026 Apr 2:djag096. doi: 10.1093.
    >> Share

    March 2026
  5. KAUL M, Scott CG, Wadzinske A, Banerjee I, et al
    Performance of clinical breast cancer risk prediction models versus a mammography-based artificial intelligence risk model.
    J Natl Cancer Inst. 2026 Mar 26:djag083. doi: 10.1093.
    >> Share

  6. KWAN ML, D'Addario L, Lee C, Roh JM, et al
    Differences in breast cancer survival across Asian American ethnicities compared with non-Latina White females in Kaiser Permanente Northern California.
    J Natl Cancer Inst. 2026 Mar 26:djag062. doi: 10.1093.
    >> Share

  7. ABOUMRAD M, Joshu C, Jackson J, Visvanathan K, et al
    Antidepressant adherence and breast cancer recurrence risk in women with major depressive disorder: a retrospective cohort.
    J Natl Cancer Inst. 2026 Mar 21:djag076. doi: 10.1093.
    >> Share

  8. YADAV S, Reid S, Yilma B, Fragkogianni S, et al
    Landscape of somatic genetic alterations and PAM50 intrinsic subtypes in breast cancer associated with germline pathogenic variants in DNA-repair genes.
    J Natl Cancer Inst. 2026 Mar 14:djag070. doi: 10.1093.
    >> Share

  9. SAMPATHKUMAR Y, Zakaria Z, O'Connell K, Bhimani J, et al
    Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer.
    J Natl Cancer Inst. 2026 Mar 4:djag063. doi: 10.1093.
    >> Share

    February 2026
  10. WOOLPERT KM, Kjaersgaard A, Schapira L, Toft Sorensen H, et al
    Opioid use after breast cancer in Denmark: a nationwide study of social and clinical factors.
    J Natl Cancer Inst. 2026 Feb 25:djag052. doi: 10.1093.
    >> Share

  11. DANIELSSON O, Dar H, Nordenskjold A, Perez-Tenorio G, et al
    Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.
    J Natl Cancer Inst. 2026 Feb 19:djag049. doi: 10.1093.
    >> Share

  12. TICKLE A, Offman J, North B, Jorgensen SF, et al
    Improved stage-specific survival in screen-detected breast cancer in Denmark: a cohort study.
    J Natl Cancer Inst. 2026 Feb 19:djaf377. doi: 10.1093.
    >> Share

  13. KORIC A, Bennett DL, Boulos F, Colditz GA, et al
    Subsequent breast cancer risk after benign biopsy in racially diverse women: Siteman Cancer Center.
    J Natl Cancer Inst. 2026 Feb 16:djag048. doi: 10.1093.
    >> Share

  14. RICHMAN IB, Lindsay ME, Long JB, Epstein E, et al
    Diagnostic yield of surveillance mammography among older women.
    J Natl Cancer Inst. 2026;118:223-230.
    >> Share

  15. TUNG N, Hollis RL, Viale G, Tweed C, et al
    Questions and answers on PARP inhibitor use in somatic BRCA-mutated breast cancers.
    J Natl Cancer Inst. 2026;118:205-213.
    >> Share

    January 2026
  16. PIMENTEL-PARRA GA, Soto-Ruiz N, Escalada-Hernandez P, San Martin-Rodriguez L, et al
    EHealth intervention for quality of life in long-term breast cancer survivors: Randomized controlled trial.
    J Natl Cancer Inst. 2026 Jan 24:djag020. doi: 10.1093.
    >> Share

  17. SHERMAN ME, Etievant L, Vierkant RA, Winham SJ, et al
    Postpartum breast cancer: evidence for a distinct phenotype.
    J Natl Cancer Inst. 2026 Jan 9:djag003. doi: 10.1093.
    >> Share

  18. LEHRER S
    Re: Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.
    J Natl Cancer Inst. 2026 Jan 8:djaf339. doi: 10.1093.
    >> Share

  19. LOWRY KP, Jeong HE, Kim KH, Hughes KS, et al
    Current state of mammography-based artificial intelligence for future breast cancer risk prediction: a systematic review.
    J Natl Cancer Inst. 2026 Jan 7:djag002. doi: 10.1093.
    >> Share

  20. IM C, Hasan H, Srinivasan A, Stene E, et al
    Breast cancer recurrence and mortality among survivors of childhood cancer.
    J Natl Cancer Inst. 2026 Jan 7:djag005. doi: 10.1093.
    >> Share

  21. WESTVOLD SJ, Long JB, Fan J, Kc M, et al
    Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer.
    J Natl Cancer Inst. 2026;118:130-140.
    >> Share

  22. BAILEY JT, Chang CJ, Gaston SA, Jackson CL, et al
    Use of hair straighteners and chemical relaxers and incidence of non-reproductive cancers.
    J Natl Cancer Inst. 2026;118:94-101.
    >> Share

    December 2025
  23. SHAO L, Wang Y, Shieh Y, Tamimi RM, et al
    Second primary cancer in breast cancer survivors by race/ethnicity and asian subgroups: a descriptive epidemiologic study.
    J Natl Cancer Inst. 2025 Dec 23:djaf372. doi: 10.1093.
    >> Share

  24. SEMPRINI J
    RE: Ambient air pollution and mortality in older patients with breast cancer.
    J Natl Cancer Inst. 2025 Dec 17:djaf369. doi: 10.1093.
    >> Share

  25. KOTSOPOULOS J, Seca M, Gronwald J, Huzarski T, et al
    Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2.
    J Natl Cancer Inst. 2025 Dec 17:djaf363. doi: 10.1093.
    >> Share

  26. JOURQUIN J, Dickerson JC, Marks EG, Epps J, et al
    Susan G. Komen's ShareForCures(R): a patient-engaged, nationwide breast cancer research registry.
    J Natl Cancer Inst. 2025 Dec 13:djaf353. doi: 10.1093.
    >> Share

  27. MATTICK LJ, Li CS, Lin PJ, Peppone LJ, et al
    Walking dose associated with lower cancer-related fatigue among patients with breast cancer.
    J Natl Cancer Inst. 2025 Dec 13:djaf360. doi: 10.1093.
    >> Share

  28. HU X, Cai C, Arshad S, Anderson JN, et al
    Potential role of perceived discrimination and sociodemographics on racial disparities in breast cancer symptom burden.
    J Natl Cancer Inst. 2025 Dec 9:djaf301. doi: 10.1093.
    >> Share

  29. SHUMWAY DA, Corbin KS, Shiraishi S, Farah MH, et al
    Comparison of partial breast radiation modalities in women with early-stage breast cancer: a target trial emulation.
    J Natl Cancer Inst. 2025 Dec 6:djaf346. doi: 10.1093.
    >> Share

  30. NASSAR AH, Bou Farhat E, Abushukair H, Alchoueriy M, et al
    Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer.
    J Natl Cancer Inst. 2025 Dec 4:djaf344. doi: 10.1093.
    >> Share

  31. HAZELWOOD E, Goudswaard LJ, Lee MA, Vabistsevits M, et al
    Adiposity distribution and risks of 12 obesity-related cancers: a Mendelian randomization analysis.
    J Natl Cancer Inst. 2025;117:2621-2642.
    >> Share

    November 2025
  32. CHOI E, Zhai W, Ahn J, Ahles TA, et al
    Neighborhood deprivation on increasing deficit accumulation in older breast cancer survivors and non-cancer controls.
    J Natl Cancer Inst. 2025 Nov 22:djaf337. doi: 10.1093.
    >> Share

  33. WORTELBOER N, Kent S, Blommestein HM, van Ommen-Nijhof A, et al
    Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial.
    J Natl Cancer Inst. 2025 Nov 21:djaf334. doi: 10.1093.
    >> Share

  34. ORLANDI A
    RE: Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer.
    J Natl Cancer Inst. 2025 Nov 5:djaf319. doi: 10.1093.
    >> Share

  35. AIELLO BOWLES EJ, O'Connell K, Bhimani J, Gallagher GB, et al
    Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancer.
    J Natl Cancer Inst. 2025 Nov 3:djaf314. doi: 10.1093.
    >> Share

  36. LIU Q, Wiese D, Pinheiro PS, Bispo JB, et al
    Association between racialized economic segregation and stage at diagnosis for 3 screenable cancers in New York City.
    J Natl Cancer Inst. 2025;117:2259-2271.
    >> Share

  37. VO JB, Brown DW, Buller ID, Shing JZ, et al
    Associations of self-identified race and ethnicity and genetic ancestry with mortality among cancer survivors.
    J Natl Cancer Inst. 2025;117:2382-2387.
    >> Share

    October 2025

  38. Correction to: Discovering plasma proteins associated with breast cancer incidence in postmenopausal women in the Atherosclerosis Risk in Communities study.
    J Natl Cancer Inst. 2025 Oct 17:djaf284. doi: 10.1093.
    >> Share

  39. OTTAVIANI D, Ola M, Allotta A, Maati Chaibi Y, et al
    Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.
    J Natl Cancer Inst. 2025 Oct 15:djaf295. doi: 10.1093.
    >> Share

  40. NADER-MARTA G, Chu X, Mukhopadhyay S, Abramson VG, et al
    Prognostic value of visually and computationally-assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030).
    J Natl Cancer Inst. 2025 Oct 11:djaf289. doi: 10.1093.
    >> Share

  41. NGUYEN THT, Jeon S, Yoon J, Park B, et al
    Independent associations between obesity, glucose metabolism, and breast cancer risk through unrelated pathways.
    J Natl Cancer Inst. 2025 Oct 8:djaf287. doi: 10.1093.
    >> Share

    September 2025
  42. SYMONDS LK, Davidson NE
    RecOVARY? Using anti-Mullerian hormone to predict ovarian function after anti-HER2 therapy for early breast cancer.
    J Natl Cancer Inst. 2025 Sep 26:djaf247. doi: 10.1093.
    >> Share

  43. SEEWALDT VL, Schedin PJ
    Breastfeeding after breast cancer: a need for further mechanistic study.
    J Natl Cancer Inst. 2025 Sep 18:djaf240. doi: 10.1093.
    >> Share

  44. IRAJIZAD E, Hanash S
    Breast cancer risk assessment: current challenges and the emerging role of blood-based protein biomarkers.
    J Natl Cancer Inst. 2025 Sep 3:djaf215. doi: 10.1093.
    >> Share

  45. PRESTI D, Di Meglio A, Havas J, Pagliuca M, et al
    Risk models of cancer related cognitive complaints among early breast cancer survivors in the CANTO cohort.
    J Natl Cancer Inst. 2025 Sep 3:djaf256. doi: 10.1093.
    >> Share

  46. SAHIN TK, Guven DC, Aksoy S
    RE: Aprepitant use during chemotherapy and association with survival in women with early breast cancer.
    J Natl Cancer Inst. 2025 Sep 3:djaf254. doi: 10.1093.
    >> Share

    August 2025
  47. CARBONE A, Oliva M, Puntoni M, Guerrieri-Gonzaga A, et al
    Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase III trial in non-invasive breast cancer.
    J Natl Cancer Inst. 2025 Aug 28:djaf250. doi: 10.1093.
    >> Share

  48. TARANTINO P, Lee D, Foldi J, Soulos PR, et al
    Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer.
    J Natl Cancer Inst. 2025 Aug 14:djaf220. doi: 10.1093.
    >> Share

  49. LAMBERTINI M, Allegranza D, Laubender RP, Harbeck N, et al
    Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.
    J Natl Cancer Inst. 2025 Aug 12:djaf198. doi: 10.1093.
    >> Share

  50. MO T, Partridge A, Joffe M, Cubasch H, et al
    Survival deficits in young women with breast cancer in Sub-Saharan africa: the ABC-DO cohort.
    J Natl Cancer Inst. 2025 Aug 7:djaf213. doi: 10.1093.
    >> Share

  51. WEI Y, Castro E, Yin K, Zhang M, et al
    Ambient air pollution and mortality in older breast cancer patients.
    J Natl Cancer Inst. 2025 Aug 5:djaf217. doi: 10.1093.
    >> Share

  52. SPOOR J, Mureau MAM, Tissier RLM, Hommes J, et al
    Breast implant illness after reconstruction with silicone breast implants.
    J Natl Cancer Inst. 2025;117:1717-1728.
    >> Share

  53. YU TT, Hoyt AC, Joines MM, Fischer CP, et al
    Mammographic classification of interval breast cancers and artificial intelligence performance.
    J Natl Cancer Inst. 2025;117:1627-1638.
    >> Share

    July 2025
  54. ZHU T, Bu J, Zhu X
    RE: Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.
    J Natl Cancer Inst. 2025 Jul 23:djaf187. doi: 10.1093.
    >> Share

  55. WATT GP, Reiner AS, Shu X, Malone KE, et al
    Polygenic risk of coronary artery disease for long-term survivors of breast cancer.
    J Natl Cancer Inst. 2025 Jul 16:djaf189. doi: 10.1093.
    >> Share

  56. BOTTERI E, Hjorth S, Conforti F, Bagnardi V, et al
    Aprepitant use during chemotherapy and association with survival in women with early breast cancer.
    J Natl Cancer Inst. 2025 Jul 14:djaf178. doi: 10.1093.
    >> Share

  57. SYLEOUNI ME, Joshu CE, Coresh J, Gunter MJ, et al
    Discovering plasma proteins associated with breast cancer incidence in post-menopausal women in ARIC.
    J Natl Cancer Inst. 2025 Jul 7:djaf170. doi: 10.1093.
    >> Share

  58. BLONDEAUX E, Delucchi V, Mariamidze E, Bernstein-Molho R, et al
    Breastfeeding after breast cancer in young BRCA carriers.
    J Natl Cancer Inst. 2025 Jul 7:djaf177. doi: 10.1093.
    >> Share

  59. STECKLEIN SR, Martin M, Villacampa G, Del Monte-Millan M, et al
    Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer.
    J Natl Cancer Inst. 2025 Jul 2:djaf162. doi: 10.1093.
    >> Share

  60. FAN Q, Dong W, Schafer EJ, Wagle NS, et al
    Changes in time-to-treatment initiation for breast, non-small cell lung, colon, or rectal cancers throughout the COVID-19 pandemic in the United States.
    J Natl Cancer Inst. 2025;117:1506-1511.
    >> Share

    June 2025
  61. ARECCO L, Blondeaux E, Bruzzone M, Arpino G, et al
    Prognostic implications of risk definitions from the monarchE and NATALEE trials.
    J Natl Cancer Inst. 2025;117:1198-1208.
    >> Share

    May 2025
  62. ABUBAKAR M, Duggan MA, Fan S, Pfeiffer RM, et al
    Unraveling the role of stromal disruption in aggressive breast cancer etiology and outcomes.
    J Natl Cancer Inst. 2025 May 14:djaf070. doi: 10.1093.
    >> Share

  63. LI D, Liu Y, Duan Q, Chen X, et al
    RE: Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis.
    J Natl Cancer Inst. 2025 May 7:djaf115. doi: 10.1093.
    >> Share

  64. TUESLEY KM, Spilsbury K, Pearson SA, Donovan P, et al
    Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers.
    J Natl Cancer Inst. 2025;117:1046-1055.
    >> Share

  65. MCWILLIAM A, Marshall D, Kerns SL, Barnett GC, et al
    Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis.
    J Natl Cancer Inst. 2025;117:1018-1026.
    >> Share

  66. BUQUE A, Bloy N, Petroni G, Jimenez-Cortegana C, et al
    Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor-positive mammary carcinogenesis.
    J Natl Cancer Inst. 2025;117:934-947.
    >> Share

    April 2025
  67. ZHANG J, Zhang L, Liu Z, Jia Y, et al
    RE: Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors.
    J Natl Cancer Inst. 2025 Apr 9:djaf093. doi: 10.1093.
    >> Share

  68. LOPEZ-FERNANDEZ A, Duran-Lozano L, Villacampa G, Pardo M, et al
    A randomized study of 2 risk assessment models for individualized breast cancer risk estimation.
    J Natl Cancer Inst. 2025 Apr 1:djaf067. doi: 10.1093.
    >> Share

  69. BARGON CA, Mink van der Molen DR, Young-Afat DA, Batenburg MCT, et al
    Clinical and patient-reported outcomes after oncoplastic vs conventional breast-conserving surgery-a longitudinal, multicenter cohort study.
    J Natl Cancer Inst. 2025;117:781-789.
    >> Share

  70. LI S, Madanat-Harjuoja L, Leslie G, Barnes DR, et al
    Childhood, adolescent, and young adulthood cancer risk in BRCA1 or BRCA2 pathogenic variant carriers.
    J Natl Cancer Inst. 2025;117:728-736.
    >> Share

  71. STROOT IAS, Bart J, Hollema H, Wagner MM, et al
    High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers.
    J Natl Cancer Inst. 2025;117:719-727.
    >> Share

  72. HAMMARSTROM M, Gabrielson M, Bergqvist J, Lundholm C, et al
    Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial.
    J Natl Cancer Inst. 2025;117:629-636.
    >> Share

    March 2025
  73. KURIAN AW, Furgal AKC, Radhakrishnan A, Veenstra CM, et al
    Extended endocrine therapy use and decision making after breast cancer diagnosis.
    J Natl Cancer Inst. 2025 Mar 31:djaf076. doi: 10.1093.
    >> Share

  74. SAMMONS SL, Sanglier T, Leone JP, Erick TK, et al
    Prevalence by therapy line and incidence of breast cancer brain metastases in 18,075 patients.
    J Natl Cancer Inst. 2025 Mar 31:djaf048. doi: 10.1093.
    >> Share

  75. LYNCE F, Niman SM, Kai M, Ma SR, et al
    Development of a Multi-Institutional Dataset to Validate a Novel Inflammatory Breast Cancer Diagnostic Score.
    J Natl Cancer Inst. 2025 Mar 31:djaf088. doi: 10.1093.
    >> Share

  76. BETTARIGA F, Taaffe DR, Borsati A, Avancini A, et al
    Effects of exercise on inflammation in female survivors of nonmetastatic breast cancer: a systematic review and meta-analysis.
    J Natl Cancer Inst. 2025 Mar 20:djaf062. doi: 10.1093.
    >> Share

  77. HUANG Y, Kwan ML, Heckbert SR, Smith NL, et al
    Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors.
    J Natl Cancer Inst. 2025 Mar 11:djaf063. doi: 10.1093.
    >> Share

    February 2025
  78. HU P, Prorok PC, Katki HA
    Design of randomized controlled trials to estimate cancer-mortality reductions from multicancer detection screening.
    J Natl Cancer Inst. 2025;117:303-311.
    >> Share

    January 2025
  79. MEZGER NCS, Seraphin TP, Balle R, Griesel M, et al
    NCCN guideline-concordant cancer care in sub-Saharan Africa: a population-based multicountry study of 5 cancers.
    J Natl Cancer Inst. 2025;117:120-133.
    >> Share

  80. GOGLIA AG, Alshalalfa M, Khan A, Isakov DR, et al
    Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers.
    J Natl Cancer Inst. 2025;117:188-197.
    >> Share

  81. GANZ PA, Cecchini RS, White JR, Vicini FA, et al
    Quality-of-life outcomes from NRG Oncology NSABP B-39/RTOG 0413: whole-breast irradiation vs accelerated partial-breast irradiation after breast-conserving surgery.
    J Natl Cancer Inst. 2025;117:103-111.
    >> Share

    December 2024
  82. ZHANG Y, Lv P
    RE: Genetic risk, health-associated lifestyle, and risk of early-onset total cancer and breast cancer.
    J Natl Cancer Inst. 2024 Dec 19:djae322. doi: 10.1093.
    >> Share

  83. LOLAS-HAMAMEH S, Lieberman S, Sarahneh A, Walsh T, et al
    TP53 missense allele predisposing to high risk of breast cancer but not pediatric cancers.
    J Natl Cancer Inst. 2024 Dec 14:djae334. doi: 10.1093.
    >> Share

  84. PETITJEAN C, Wilcox N, Ficorella L, Dennis J, et al
    Evaluating the performance of the BOADICEA model in predicting 10-year breast cancer risks in UK Biobank.
    J Natl Cancer Inst. 2024 Dec 12:djae335. doi: 10.1093.
    >> Share

  85. ABDOU Y, Barlow WE, Gralow JR, Meric-Bernstam F, et al
    Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial.
    J Natl Cancer Inst. 2024 Dec 5:djae314. doi: 10.1093.
    >> Share

  86. PALMER S, Valachis A, Lindman H, Smith DR, et al
    Omission of postoperative radiotherapy after breast-conserving surgery in low-risk breast cancer.
    J Natl Cancer Inst. 2024 Dec 4:djae315. doi: 10.1093.
    >> Share

  87. JOHANSSON A, Dar H, Nordenskjold A, Perez-Tenorio G, et al
    Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.
    J Natl Cancer Inst. 2024 Dec 4:djae268. doi: 10.1093.
    >> Share

  88. SERRANO D, Johansson H, Bertelsen BE, Gandini S, et al
    Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules.
    J Natl Cancer Inst. 2024;116:1979-1982.
    >> Share

  89. ARTESE AL, Zhou X, Tometich DB, Small BJ, et al
    Physical activity and cognition: longitudinal findings from the Thinking and Living with Cancer Study.
    J Natl Cancer Inst. 2024;116:2009-2021.
    >> Share

  90. ELZE L, van der Post RS, Vos JR, Mensenkamp AR, et al
    Genomic instability in non-breast or ovarian malignancies of individuals with germline pathogenic variants in BRCA1/2.
    J Natl Cancer Inst. 2024;116:1904-1913.
    >> Share

    November 2024
  91. GRAFF SL, Tinianov S, Kalinsky K
    "Nailing down" risk and improving outcomes in early-stage breast cancer.
    J Natl Cancer Inst. 2024 Nov 22:djae278. doi: 10.1093.
    >> Share

  92. ROMANOS-NANCLARES A, Willett WC, Rosner B, Stover DG, et al
    Proinflammatory Dietary Pattern and Risk of Total and Subtypes of Breast Cancer Among U.S. Women.
    J Natl Cancer Inst. 2024 Nov 20:djae301. doi: 10.1093.
    >> Share

  93. ABOUMRAD M, Joshu C, Visvanathan K
    Impact of major depressive disorder on breast cancer outcomes: a national retrospective cohort study.
    J Natl Cancer Inst. 2024 Nov 12:djae287. doi: 10.1093.
    >> Share

  94. ROBERTI S, van Leeuwen FE, Diallo I, de Vathaire F, et al
    Prediction of breast cancer risk for adolescents and young adults with Hodgkin lymphoma.
    J Natl Cancer Inst. 2024 Nov 1:djae274. doi: 10.1093.
    >> Share

    October 2024
  95. FOSTER VM, Trentham-Dietz A, Stout NK, Lee CI, et al
    Supplemental breast cancer screening after negative mammography in U.S. women with dense breasts.
    J Natl Cancer Inst. 2024 Oct 30:djae272. doi: 10.1093.
    >> Share

  96. KJAERGAARD KA, Kousholt A, Thomsen RW, Woolpert KM, et al
    Risk of type-2-diabetes after breast cancer treatment: a population-based cohort study in Denmark.
    J Natl Cancer Inst. 2024 Oct 22:djae261. doi: 10.1093.
    >> Share

  97. KARLSSON P, Fyles A, Chang SL, Arrick B, et al
    Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis.
    J Natl Cancer Inst. 2024 Oct 18:djae262. doi: 10.1093.
    >> Share

  98. ROMANOS-NANCLARES A, Schernhammer E, Willett WC, Holmes MD, et al
    Consumption of aspartame and risk of breast cancer in the Nurses' Health Studies.
    J Natl Cancer Inst. 2024 Oct 17:djae259. doi: 10.1093.
    >> Share

  99. SHERMAN ME, Winham SJ, Vierkant RA, Mccauley BM, et al
    Polygenic risk scores stratify breast cancer risk among women with benign breast disease.
    J Natl Cancer Inst. 2024 Oct 16:djae255. doi: 10.1093.
    >> Share

  100. JOHN EM, Koo J, Ingles SA, Keegan TH, et al
    Risk factors for second primary breast cancer by laterality, age, and race and ethnicity.
    J Natl Cancer Inst. 2024 Oct 11:djae254. doi: 10.1093.
    >> Share

  101. WATTS EL, Moore SC, Abar L, Hong HG, et al
    Physical activity, metabolites, and breast cancer associations.
    J Natl Cancer Inst. 2024 Oct 9:djae246. doi: 10.1093.
    >> Share

  102. CARROLL JE, Crespi CM, Cole S, Ganz PA, et al
    Transcriptomic markers of biological aging in breast cancer survivors: a longitudinal study.
    J Natl Cancer Inst. 2024 Oct 8:djae201. doi: 10.1093.
    >> Share

    September 2024
  103. MARCZYK M, Kahn A, Silber A, Rosenblit M, et al
    Trends in breast cancer specific death by clinical stage at diagnoses between 2000-2017.
    J Natl Cancer Inst. 2024 Sep 30:djae241. doi: 10.1093.
    >> Share

  104. PAGLIUCA M, Havas J, Thomas E, Drouet Y, et al
    Long-term behavioral symptom clusters among survivors of early-stage breast cancer. development and validation of a predictive model.
    J Natl Cancer Inst. 2024 Sep 9:djae222. doi: 10.1093.
    >> Share

  105. DAS S, Wentzensen N, Sawaya GF, Egemen D, et al
    Primary human papillomavirus testing vs cotesting: clinical outcomes in populations with different disease prevalence.
    J Natl Cancer Inst. 2024;116:1525-1529.
    >> Share

  106. MANDELBLATT J, Dage JL, Zhou X, Small BJ, et al
    Alzheimer disease-related biomarkers and cancer-related cognitive decline: the Thinking and Living with Cancer study.
    J Natl Cancer Inst. 2024;116:1495-1507.
    >> Share

    August 2024
  107. ZHANG Y, Lindstrom S, Kraft P, Liu Y, et al
    Genetic Risk, Health-Associated Lifestyle, and Risk of Early-onset Total Cancer and Breast Cancer.
    J Natl Cancer Inst. 2024 Aug 27:djae208. doi: 10.1093.
    >> Share

  108. EBRAHIMOGHLI R, Aghaei MH, Azami-Aghdash S, Houssami N, et al
    Uptake of Breast Cancer Screening Practices in Low and Middle-Income Countries: A Systematic Review and Meta-Analysis.
    J Natl Cancer Inst. 2024 Aug 12:djae187. doi: 10.1093.
    >> Share

  109. FOLDI J, Carleton N, Anderson SJ, Rastogi P, et al
    Long-term outcomes by lobular versus ductal histology in four NSABP adjuvant breast cancer trials.
    J Natl Cancer Inst. 2024 Aug 10:djae188. doi: 10.1093.
    >> Share

  110. MALAGON T
    Time to change the paradigm for primary endpoints in cancer screening trials?
    J Natl Cancer Inst. 2024;116:1187-1189.
    >> Share

    July 2024
  111. MASSA D, Vernieri C, Nicole L, Criscitiello C, et al
    Immune and Gene-expression Profiling in Estrogen Receptor Low and Negative Early Breast Cancer.
    J Natl Cancer Inst. 2024 Jul 31:djae178. doi: 10.1093.
    >> Share

  112. HURSON AN, Ahearn TU, Koka H, Jenkins BD, et al
    Risk factors for breast cancer subtypes by race and ethnicity: A scoping review.
    J Natl Cancer Inst. 2024 Jul 17:djae172. doi: 10.1093.
    >> Share

  113. ZHENG G, Baandrup L, Wang J, Hertzum-Larsen R, et al
    Ovarian cancer risk factors in relation to family history.
    J Natl Cancer Inst. 2024 Jul 4:djae164. doi: 10.1093.
    >> Share

    June 2024
  114. DENT R, Cortes J, Pusztai L, McArthur H, et al
    Neoadjuvant pembrolizumab+chemotherapy/adjuvant pembrolizumab for Early-Stage Triple-Negative breast cancer: Quality-of-Life results from randomized KEYNOTE-522 study.
    J Natl Cancer Inst. 2024 Jun 24:djae129. doi: 10.1093.
    >> Share

  115. JAGUST P, Powell AM, Ola M, Watson L, et al
    RET overexpression leads to increased brain metastatic competency in luminal breast cancer.
    J Natl Cancer Inst. 2024 Jun 10:djae091. doi: 10.1093.
    >> Share

  116. CHUA AV JR, Sheng H, Liang E, Gandhi S, et al
    Epidemiology of early vs. Late recurrence among women with Early-Stage estrogen Receptor-Positive breast cancer in the pathways study.
    J Natl Cancer Inst. 2024 Jun 6:djae128. doi: 10.1093.
    >> Share

  117. LIN J, Ouyang Y, Li Y, Jin L, et al
    Different dosage forms of GnRHa with endocrine therapy in premenopausal hormone Receptor-Positive breast cancer.
    J Natl Cancer Inst. 2024 Jun 4:djae115. doi: 10.1093.
    >> Share

    May 2024

  118. Correction to: Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy.
    J Natl Cancer Inst. 2024 May 8:djae093. doi: 10.1093.
    >> Share

  119. VO JB, Ramin C, Veiga LHS, Brandt C, et al
    Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in U.S. breast cancer survivors.
    J Natl Cancer Inst. 2024 May 8:djae107. doi: 10.1093.
    >> Share

    April 2024
  120. OMOLEYE OJ, Esserman LJ, Olopade OI
    RE: Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density.
    J Natl Cancer Inst. 2024;116:627-628.
    >> Share

  121. VILLY MC, Le Ven A, Le Mentec M, Masliah-Planchon J, et al
    Familial uveal melanoma and other tumors in 25 families with monoallelic germline MBD4 variants.
    J Natl Cancer Inst. 2024;116:580-587.
    >> Share

  122. SANDOVAL RL, Bottosso M, Tianyu L, Polidorio N, et al
    TP53-associated early breast cancer: new observations from a large cohort.
    J Natl Cancer Inst. 2024 Apr 3:djae074. doi: 10.1093.
    >> Share

    March 2024
  123. ZENG E, He W, Sjolander A, Bergqvist J, et al
    Familial adversity: association with discontinuation of adjuvant hormone therapy and breast cancer prognosis.
    J Natl Cancer Inst. 2024 Mar 12:djae061. doi: 10.1093.
    >> Share

  124. HUBBARD RA, Su YR, Bowles EJ, Ichikawa L, et al
    Predicting five-year interval second breast cancer risk in women with prior breast cancer.
    J Natl Cancer Inst. 2024 Mar 11:djae063. doi: 10.1093.
    >> Share

  125. LEE CI, Elmore JG
    Beyond survival: a closer look at lead-time bias and disease-free intervals in mammography screening.
    J Natl Cancer Inst. 2024;116:343-344.
    >> Share

  126. KUMAR N, Ehsan S, Banerjee S, Fernandez Perez C, et al
    The unique risk factor profile of triple negative breast cancer: a comprehensive meta-analysis.
    J Natl Cancer Inst. 2024 Mar 5:djae056. doi: 10.1093.
    >> Share

    February 2024
  127. LI JL, McClellan JC, Zhang H, Gao G, et al
    Multi-tissue transcriptome-wide association studies identified 235 genes for intrinsic subtypes of breast cancer.
    J Natl Cancer Inst. 2024 Feb 23:djae041. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016